HDAX Therapeutics is pioneering best-in-class therapeutics for neurological and cardiovascular diseases by targeting the root causes of these diseases. Leveraging our molecular recognition platform technology, we have engineered a novel 2-site binding mechanism targeting HDAC6, a key protein implicated in microtubule dysfunction. Our innovative approach addresses critical drug-design obstacles, including weak binding, off-target toxicities, and suboptimal pharmacokinetic profiles, unlocking the potential to translate into better treatments for patients. Our initial focus is peripheral neuropathies (chemotherapy-induced peripheral neuropathy and Charcot-Marie-Tooth), and additional applications include heart failure and neurodegeneration. HDAX is a spinout from Prof. Patrick Gunning’s lab at University of Toronto, a successful serial entrepreneur (Janpix, Dunad, & Dalriada Therapeutics).